An ehealth model of care for community treatment of hepatitis C: The HealthElink study

Size: px
Start display at page:

Download "An ehealth model of care for community treatment of hepatitis C: The HealthElink study"

Transcription

1 Dr James Haridy MBBS B.Physio MPH Gastroenterology & Hepatology Fellow, PhD Candidate Royal Melbourne Hospital / University of Melbourne An ehealth model of care for community treatment of hepatitis C: The HealthElink study

2 230,000 Australians Infected1

3 SUSTAINED VIROLOGICAL RESPONSE We are at an incredible point in history. 95% 100% 80% 70% 60% 40% 20% 7% 25% 45% 0% YEAR Ref 2,3

4 The first 12-months Why do we need GPs to prescribe this treatment? And what are the barriers in the current model of care? Ref 4

5 The current problems.. Difficult to reach high-risk populations Prisons Stigma Concerned about loss to followup People Cannot Potential Who attend for Inject specialist missing cirrhosis Drugs / hospital Mental Capacity Rural/Remote and access Health Indigenous Cost Simply do not turn up Specialist GP Nurse Patient

6 The HealthElink system GP / Nurse / Specialist Portals Patient Portal

7 The HealthElink system Complex treatment algorithm Multiple treatment plans based on hepatitis C type, fibrosis assessment and medication interactions Security Ernst and Young engaged to advised on security, including code review and penetration testing. Corrs Chambers Westgarth engaged to provide advice on health data privacy compliance. Data storage on HIPAA compliant Amazon Web Servers

8 The HealthElink study Aim To determine the feasibility, efficacy and acceptability of an ehealth system in the community treatment of hepatitis C

9 Timeline Development HealthElink Study

10 1. Usability study 16 users in total over two early versions Median time for referral HealthElink 538 v 552 seconds v Correct treatment regimen prescribed in 12/12 (100%) using HealthElink compared with 9/12 (75%) using current paper based form 12/12 (100%) preferred use of the HealthElink system

11 2. The HealthElink Study Prospective multicenter trial Target 500 non-specialist referrals Prison services in NT / SA

12 3. Qualitative study planned in 2018 Late 2018, purposive sampling of representative usage groups Users displaying both high and low activity on the system to be interviewed in semi-structured interview Explore acceptability and motivation behind uptake (or non-uptake) of the system

13 The future plan Trial in other chronic diseases Further funding to develop system further, enhance compatibility Mobile / app development to enhance patient experience and interactivity Refine based on user feedback

14 In Summary Hepatitis C now can be cured, but we still need to get the cure out there Deficiencies in the traditional model of care preclude rapid and widespread implementation in primary care An ehealth model of care offers a solution to overcome many of the barriers to eradication

15 Acknowledgments & Declarations HealthElink has received funding grants from the Royal Melbourne Foundation, Merck-Sharpe-Dohme and Bristol-Myers-Squibb For more information, visit This research would not be possible without many others: Dr Guru Iyngkaran Dr Edmund Tse Dr Suresh Sivanesan Dr Rodney Omond Dr Jacqui Richmond DB Results Hepatitis Australia Mr Ian Baker The Adelaide Liver Group Prof Meredith Temple-Smith Shine SA A/Prof Amanda Nicoll A/Prof Geoff Hebbard Prof Danny Liew Adelaide and Rural SA PHN ASHM

16 References Hepatitis C Image: Piver E, Boyer A, Gaillard J, Bull A, Beaumont E, Roingeard P, et al. Ultrastructural organisation of HCV from the bloodstream of infected patients revealed by electron microscopy after specific immunocapture. Gut. BMJ Publishing Group; 2017 Aug;66(8): Liver Cirrhosis Image: Courtesy 1. Hajarizadeh B, Grebely J, McManus H, et al. Chronic hepatitis C burden and treatment uptake in Australia: updated figures at the beginning of a new era [abstract]. HEP DART 2015: Frontiers in Drug Development for Viral Hepatitis. Global Antiviral Journal 2015; 11 Suppl 3: Chart adapted from information contained in: Bertino G, Ardiri A, Proiti M, Rigano G, Frazzetto E, Demma S, et al. Chronic hepatitis C: This and the new era of treatment. WJH. Baishideng Publishing Group Inc; 2016 Jan 18;8(2): Australian Federal Government, Department of Health and Aging. Media Release 22 nd December Turnbull Government Invests over $1B to cure Hep C. Accessible from: 4. The Kirby Institute. Monitoring Hepatitis C treatment uptake in Australia July pp Rubin J, Chisnell D. Handbook of Usability Testing. John Wiley & Sons; p.

Hepatitis C Elimination: Australia s progress

Hepatitis C Elimination: Australia s progress Hepatitis C Elimination: Australia s progress Margaret Hellard Burnet Institute, Melbourne Disclosures I receive fellowship support from the National Health and Medical Research Council (Australia). The

More information

DAA Therapy and Reinfection Among People who Inject Drugs: Forming a Foundation for HCV Elimination

DAA Therapy and Reinfection Among People who Inject Drugs: Forming a Foundation for HCV Elimination DAA Therapy and Reinfection Among People who Inject Drugs: Forming a Foundation for HCV Elimination Associate Professor Jason Grebely HEP DART 2017, Kohala Coast, Hawaii, 3 rd December 2017 Disclosures

More information

29/09/2014. Expanding access to hepatitis C treatment through primary care: Challenges and opportunities. Disclosures

29/09/2014. Expanding access to hepatitis C treatment through primary care: Challenges and opportunities. Disclosures 2013 Viremic Cases 29/09/2014 Expanding access to hepatitis C treatment through primary care: Challenges and opportunities Professor Greg Dore Kirby Institute, UNSW Australia; & St Vincent s Hospital,

More information

CURING HEPATITIS C IN GENERAL PRACTICE: THE FIRST 60 DAYS

CURING HEPATITIS C IN GENERAL PRACTICE: THE FIRST 60 DAYS CURING HEPATITIS C IN GENERAL PRACTICE: THE FIRST 60 DAYS Baker D 1,2, McMurchie M 1, Rodgers C 1, Farr V 1, Williams M 1 1 East Sydney Doctors, 2 Australasian Society for HIV Medicine 1 Disclosures Advisory

More information

Monitoring hepatitis C treatment uptake in Australia

Monitoring hepatitis C treatment uptake in Australia Monitoring hepatitis C treatment uptake in Australia Issue #7 July 217 1 Initiations of new treatment for chronic hepatitis C in 216 An estimated 32,4 individuals initiated direct acting antiviral (DAA)

More information

Integrating hepatitis C treatment in a regional setting The Cairns Experience. DANA 2018 Morag Goodinson

Integrating hepatitis C treatment in a regional setting The Cairns Experience. DANA 2018 Morag Goodinson Integrating hepatitis C treatment in a regional setting The Cairns Experience DANA 2018 Morag Goodinson I would like to acknowledge the Traditional Owners of the land, and pay respect to Elders past, present

More information

>Hepatitis NSW will continue to

>Hepatitis NSW will continue to Continued Equal Treatment Access to hepatitis C medicines KURT SAYS Everyone with viral hepatitis deserves equal access to treatment. Thankfully Australians can access hepatitis C treatment before they

More information

Hepatitis B Clinical Specialists: responding to cultural diversity. Jack Wallace Australian Research Centre in Sex, Health and Society

Hepatitis B Clinical Specialists: responding to cultural diversity. Jack Wallace Australian Research Centre in Sex, Health and Society Hepatitis B Clinical Specialists: responding to cultural diversity. Jack Wallace Australian Research Centre in Sex, Health and Society Background Hepatitis B = cultural diversity 56% of people with hepatitis

More information

Centre for Social Research in Health, UNSW Australia, NSW, Australia

Centre for Social Research in Health, UNSW Australia, NSW, Australia Qualitative study of the decisions and experiences of people who inject drugs who received a liver disease assessment as part of a liver health promotion campaign: The LiveRLife Study A.D. Marshall a,

More information

in chronic hepatitis C in Australia

in chronic hepatitis C in Australia Real world efficacy of antiviral therapy in chronic hepatitis C in Australia Issue #2 July 2018 1 Uptake and outcomes of new treatment for chronic hepatitis C during 20-20 in the REACH-C network The REACH-C

More information

People with bleeding disorders and hepatitis C

People with bleeding disorders and hepatitis C August 2017 People with bleeding disorders and hepatitis C A fact sheet for general practitioners KEY POINTS Many Australians with haemophilia, von Willebrand disease and other bleeding disorders acquired

More information

9/29/2014. Conflict of interest. Introduction: National strategy. Traditional model for hepatitis C treatment. Background: models of care

9/29/2014. Conflict of interest. Introduction: National strategy. Traditional model for hepatitis C treatment. Background: models of care Treating Hepatitis C in Primary Care: Results from a pilot program Conflict of interest David Baker: Travel grants, advisory board membership, speakers payments, preparation of educational material, clinical

More information

HCV: how do we reach elimination from a clinicians perspective. A/Professor Gail Matthews

HCV: how do we reach elimination from a clinicians perspective. A/Professor Gail Matthews HCV: how do we reach elimination from a clinicians perspective A/Professor Gail Matthews WHO global hepatitis elimination goals by 2030 Elimination a reduction in HCV incidence and HCVrelated mortality

More information

Hepatitis C epidemiology, screening and treatment

Hepatitis C epidemiology, screening and treatment Hepatitis C epidemiology, screening and treatment Date Presenter Wednesday 29 August 2018: 7.00-8.00pm Professor Greg Dore This education activity has been developed in association with: Kirby Institute,

More information

Factsheet: New Treatments for hepatitis C Direct Acting Antivirals (DAAs)

Factsheet: New Treatments for hepatitis C Direct Acting Antivirals (DAAs) Factsheet: New Treatments for hepatitis C Direct Acting Antivirals (DAAs) For more information about anything in this factsheet, phone the Hepatitis Infoline on 1800 703 003 or go to www.hepvic.org.au

More information

Surveillance and Treatment of Prisoners with hepatitis C (SToP-C) Professor Andrew Lloyd Wednesday 7 th October 2015

Surveillance and Treatment of Prisoners with hepatitis C (SToP-C) Professor Andrew Lloyd Wednesday 7 th October 2015 Surveillance and Treatment of Prisoners with hepatitis C (SToP-C) Professor Andrew Lloyd Wednesday 7 th October 2015 Australian prison population 30,775 5% 34 92% Total population Increase from 2012 Median

More information

Hepatitis C capacity strengthening program with Aboriginal Medical Services in regional Australia

Hepatitis C capacity strengthening program with Aboriginal Medical Services in regional Australia Hepatitis C capacity strengthening program with Aboriginal Medical Services in regional Australia Written and presented by: Beth Wilson ASHM is a signatory to the ACFID Code of Conduct and is committed

More information

HCV screening in Australia What we do now, and what we hope to do in future? Professor Gregory Dore

HCV screening in Australia What we do now, and what we hope to do in future? Professor Gregory Dore HCV screening in Australia What we do now, and what we hope to do in future? Professor Gregory Dore Disclosures Research grants, travel support, and honoraria: AbbVie, Gilead, Merck HCV screening in Australia

More information

HepCure : An innovative web-based toolkit to support the treatment of hepatitis C at community health centers in New York State

HepCure : An innovative web-based toolkit to support the treatment of hepatitis C at community health centers in New York State HepCure : An innovative web-based toolkit to support the treatment of hepatitis C at community health centers in New York State CHCANYS 15: Statewide Conference & Clinical Forum October 19, 2015 Jeffrey

More information

Eliminating Viral Hepatitis in Australia: Where are we in 2017?

Eliminating Viral Hepatitis in Australia: Where are we in 2017? This document was prepared by Hepatitis Australia in consultation with a variety of stakeholders working in the areas of hepatitis B and hepatitis C in Australia. This included people involved in primary

More information

Hepatitis C: a treatment revolution

Hepatitis C: a treatment revolution Sunday, 10th July 2016 Michaelmas Cay 2 Room Concurrent 11 Health Innovation Hepatitis C: a treatment revolution Dr. Heather McNamee Hepatitis C a treatment revolution Dr Heather McNamee Medical Director

More information

Outcome Statement: National Stakeholders Meeting on Quality Use of Medicines to Optimise Ageing in Older Australians

Outcome Statement: National Stakeholders Meeting on Quality Use of Medicines to Optimise Ageing in Older Australians Outcome Statement: National Stakeholders Meeting on Quality Use of Medicines to Optimise Ageing in Older Australians Executive summary Australia has a significant opportunity to improve the quality use

More information

Chronic hepatitis B. A clinical audit of GP management. Hepatitis B virus (HBV) infection represents a growing health burden

Chronic hepatitis B. A clinical audit of GP management. Hepatitis B virus (HBV) infection represents a growing health burden professional Anouk Dev James Ngoc Huong Nguyen Lili Munafo Eve Hardie Linda Iacono Chronic hepatitis B A clinical audit of GP management Background Hepatitis B virus (HBV) infection represents a growing

More information

Midlands and East Hepatitis C Educational Event Summary Report

Midlands and East Hepatitis C Educational Event Summary Report Midlands and East Hepatitis C Educational Event Summary Report Friday 10 th February 2017, Nottingham Background The Midlands and East Hepatitis C Educational Event took place on Friday 10 th February

More information

Factsheet: Treatments for hepatitis C Direct Acting Antivirals (DAAs)

Factsheet: Treatments for hepatitis C Direct Acting Antivirals (DAAs) Factsheet: Treatments for hepatitis C Direct Acting Antivirals (DAAs) For more information about anything in this factsheet, phone the Hepatitis Infoline on 1800 703 003 or go to www.hepvic.org.au The

More information

HCV elimination : lessons from Scotland

HCV elimination : lessons from Scotland HCV elimination : lessons from Scotland Sharon Hutchinson Glasgow Caledonian University / Health Protection Scotland BHIVA Hepatology Highlights, Edinburgh, 17 th April 2018 Disclosures Honoraria from

More information

PCORI s Hepatitis C Workshop. Arlington, VA October 17, 2014

PCORI s Hepatitis C Workshop. Arlington, VA October 17, 2014 PCORI s Hepatitis C Workshop Arlington, VA October 17, 2014 1 Plenary Session: Review and Discussion of Prioritized CER Questions Eric B. Bass, MD Director, Johns Hopkins Evidence-based Practice Center

More information

Inlife an online social support platform for caregivers of people with dementia Marjolein de Vugt

Inlife an online social support platform for caregivers of people with dementia Marjolein de Vugt Inlife an online social support platform for caregivers of people with dementia Marjolein de Vugt Alieske Dam Martin van Boxtel Frans Verhey Outline Background Development of the online platform Research

More information

9/26/2014. Epidemiology of chronic hepatitis B in key priority populations. Declaration of Interest. Advisory. Prevalence - similarities

9/26/2014. Epidemiology of chronic hepatitis B in key priority populations. Declaration of Interest. Advisory. Prevalence - similarities Epidemiology of chronic hepatitis B in key priority populations Declaration of Interest I receive no funding of any kind from any pharmaceutical company Benjamin Cowie WHO Regional Reference Laboratory

More information

Treatment and Prevention to Eliminate Hepatitis C. The TAP Study. Margaret Hellard

Treatment and Prevention to Eliminate Hepatitis C. The TAP Study. Margaret Hellard Treatment and Prevention to Eliminate Hepatitis C. The TAP Study Margaret Hellard Declarations NHMRC fellowship Burnet receives infrastructure support from the Victorian Government Gilead Sciences Abbvie

More information

Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France

Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France 9th Paris Hepatitis Conference, January 11-12, 2016 Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France Disclosures

More information

RECOMMENDATION FOR THE MANAGEMENT OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS

RECOMMENDATION FOR THE MANAGEMENT OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS RECOMMENDATION FOR THE MANAGEMENT OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS The International Network on Hepatitis in Substance users (INHSU) Olav Dalgard Oslo Grebely J et al Int J

More information

Setting the Stage Key Challenges in Elimination

Setting the Stage Key Challenges in Elimination Setting the Stage Key Challenges in Elimination Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto Disclosures Consulting: Abbvie, Contravir,

More information

HCV Action and Bristol & Severn ODN workshop, 14 th September 2017: Summary report

HCV Action and Bristol & Severn ODN workshop, 14 th September 2017: Summary report HCV Action and Bristol & Severn ODN workshop, 14 th September 2017: Summary report About HCV Action HCV Action is a network, co-ordinated by The Hepatitis C Trust, that brings together health professionals

More information

Micro-elimination. A path to global elimination of hepatitis C. Prof Jeffrey V. Lazarus

Micro-elimination. A path to global elimination of hepatitis C. Prof Jeffrey V. Lazarus Micro-elimination A path to global elimination of hepatitis C Prof Jeffrey V. Lazarus [Jeffrey.Lazarus@isglobal.org] Associate Researcher/Assoc Professor, ISGlobal, Hospital Clínic, University of Barcelona

More information

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,

More information

Current Hepatitis B and C Screening Practices for Migrants and Barriers to Screening

Current Hepatitis B and C Screening Practices for Migrants and Barriers to Screening Current Hepatitis B and C Screening Practices for Migrants and Barriers to Screening Amena Ahmad, Ralf Reintjes Hamburg University of Applied Sciences, Germany European Conference on Migrant and Ethnic

More information

Update in hepatitis C virus infection

Update in hepatitis C virus infection Update in hepatitis C virus infection Eoin Feeney Consultant in Infectious Diseases St. Vincent s University Hospital Overview Natural history Diagnosis, screening, staging Management Barriers going forward

More information

HCV ACTION EAST OF ENGLAND HEPATITIS C GOOD PRACTICE ROADSHOW, 9TH MAY 2017 SUMMARY REPORT

HCV ACTION EAST OF ENGLAND HEPATITIS C GOOD PRACTICE ROADSHOW, 9TH MAY 2017 SUMMARY REPORT HCV ACTION EAST OF ENGLAND HEPATITIS C GOOD PRACTICE ROADSHOW, 9TH MAY 2017 SUMMARY REPORT Introduction With hepatitis C representing a significant public health concern in the Cambridge and East of England

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal Review of TA96; Adefovir dipivoxil and peginterferon alfa-2a for

More information

The PERISCOPE Study. 13th Australian Palliative Care Conference 1-4 September, 2015 Melbourne, Australia

The PERISCOPE Study. 13th Australian Palliative Care Conference 1-4 September, 2015 Melbourne, Australia The PERISCOPE Study 13th Australian Palliative Care Conference 1-4 September, 2015 Melbourne, Australia Perceptions, Impact and Scope of Opioid medication Errors in adult palliative care and oncology services.

More information

HCV treatment in Australia: a new role for GPs

HCV treatment in Australia: a new role for GPs Disclosures HCV treatment in Australia: a new role for GPs Dr David Iser The Alfred & St. Vincent s Hospitals 15 th October 2016 I have received honoraria for presentations and/or consultancies from: AbbVie

More information

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Daklinza Sovaldi Page: 1 of 4 Last Review Date: September 18, 2015 Daklinza Sovaldi Description

More information

Hepatitis C Strategy. About us. What is hepatitis C?

Hepatitis C Strategy. About us. What is hepatitis C? Hepatitis C Strategy About us We support people to take control of their lives and make positive changes. For fifty years we have made a difference to people who want to change their relationship with

More information

Access to HCV treatment in Egypt

Access to HCV treatment in Egypt Access to HCV treatment in Egypt Prof. Gamal Esmat Prof. Hepatology &Vice President of Cairo University, Egypt Member of WHO Strategic Committee for Viral Hepatitis www.gamalesmat.com Global genotype distribution

More information

HEPATITIS B: WHO AND WHEN TO TREAT?

HEPATITIS B: WHO AND WHEN TO TREAT? HEPATITIS B: WHO AND WHEN TO TREAT? George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department of

More information

Stable incidence of hepatitis C virus infection among PWID in an Australian prison setting, : the HITS-p study

Stable incidence of hepatitis C virus infection among PWID in an Australian prison setting, : the HITS-p study Stable incidence of hepatitis C virus infection among PWID in an Australian prison setting, 2005-2014: the HITS-p study Evan B. Cunningham 1, Brigid Betz-Stablein 2, Neil A. Bretana 2, Gregory J. Dore

More information

Patient-Centered Hepatitis C Virus (HCV) Care Via Telemedicine for Individuals on Opiate Agonist Treatment Marija Zeremski, PhD

Patient-Centered Hepatitis C Virus (HCV) Care Via Telemedicine for Individuals on Opiate Agonist Treatment Marija Zeremski, PhD Patient-Centered Hepatitis C Virus (HCV) Care Via Telemedicine for Individuals on Opiate Agonist Treatment Marija Zeremski, PhD Project Director Clinical Directors Network, Inc. Training Overview Brief

More information

Case Study: Physician and Patient-Facing Medical Education APPs. Sandeep Pulim, MD Chief Medical Information Officer

Case Study: Physician and Patient-Facing Medical Education APPs. Sandeep Pulim, MD Chief Medical Information Officer Case Study: Physician and Patient-Facing Medical Education APPs Sandeep Pulim, MD Chief Medical Information Officer Quality IME Collaborating for Patient Care Commercial Supporter Medical Education Provider

More information

Will HCV therapies deliver global impact? Professor Greg Dore

Will HCV therapies deliver global impact? Professor Greg Dore Will HCV therapies deliver global impact? Professor Greg Dore Disclosures Gregory Dore has received research grants awarded to his institution from Gilead, Bristol Myers Squibb, Abbvie, Merck, and Janssen;

More information

PEOS. Powering Patient Engagement in Hepatitis C treatment in Community Settings.

PEOS. Powering Patient Engagement in Hepatitis C treatment in Community Settings. PEOS Powering Patient Engagement in Hepatitis C treatment in Community Settings. INTRODUCTION Hepatitis C is a liver infection caused by the hepatitis C Virus which can result in inflammation and fibrosis

More information

The Impact of HBV Therapy on Fibrosis and Cirrhosis

The Impact of HBV Therapy on Fibrosis and Cirrhosis The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for

More information

Bruce Kreter, PharmD Senior Director, Global HCV Medical Affairs Gilead Sciences, Inc.

Bruce Kreter, PharmD Senior Director, Global HCV Medical Affairs Gilead Sciences, Inc. CDC Foundation & Viral Hepatitis Action Coalition: Summit for the Elimination of Hepatitis B and Hepatitis C as Public Health Threats in the United States Bruce Kreter, PharmD Senior Director, Global HCV

More information

An Oncology Digital Companion for Patient-Reported Outcomes with Electronic Health Record Integration. Dr Zachary Tan

An Oncology Digital Companion for Patient-Reported Outcomes with Electronic Health Record Integration. Dr Zachary Tan An Oncology Digital Companion for Patient-Reported Outcomes with Electronic Health Record Integration Dr Zachary Tan A Diagnosis Of Cancer Is Devastating Shocked Confused Disorganized Alone The Digital

More information

We know DAAs work for PWID, now what? Simplifying HCV testing, linkage to care and treatment

We know DAAs work for PWID, now what? Simplifying HCV testing, linkage to care and treatment We know DAAs work for PWID, now what? Simplifying HCV testing, linkage to care and treatment Associate Professor Jason Grebely National Drug & Alcohol Research Centre, Sydney, Australia, 17 th May 2018

More information

Hepatitis C at W 17th St Family Practice

Hepatitis C at W 17th St Family Practice Hepatitis C at W 17th St Family Practice Identifying population needs and proposing a clinical workflow Meg Glausser, Regina Ginzburg, Shireen Farzadeh, You Jin Chang, Michelle Bejar Background & Rationale

More information

ANMF NATIONAL PRACTICE STANDARDS FOR NURSES IN GENERAL PRACTICE

ANMF NATIONAL PRACTICE STANDARDS FOR NURSES IN GENERAL PRACTICE Hepatitis C Primary Health Care Nurses (PHCNs) can play a critical role in utilising their chronic disease management skills to support the testing, diagnosis and management of people with chronic hepatitis

More information

TREATMENT OF RECENTLY ACQUIRED HEPATITIS C VIRUS INFECTION (ATAHC II)

TREATMENT OF RECENTLY ACQUIRED HEPATITIS C VIRUS INFECTION (ATAHC II) TREATMENT OF RECENTLY ACQUIRED HEPATITIS C VIRUS INFECTION (ATAHC II) A national study to find the best treatment strategy for people with recently acquired hepatitis C infection. introduction This information

More information

HCV DAA Imports Failing to Deliver Results:

HCV DAA Imports Failing to Deliver Results: + HCV DAA Imports Failing to Deliver Results: SVR12 outcomes for imported DAA s in the T Matthew Maddison, Suresh Sharma, Craig Boutlis, Kirsty Campbell, Jane Davies & Catherine Marshall Viral Hepatitis

More information

Patient navigators for hepatitis C patients found useful in New York City

Patient navigators for hepatitis C patients found useful in New York City CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Patient navigators for hepatitis C patients found useful in New York City 4 January 2017 Hepatitis C virus (HCV) infects and injures the

More information

Felice Nava, MD, PhD Felice A. Nava, MD PhD

Felice Nava, MD, PhD Felice A. Nava, MD PhD Felice Nava, MD, PhD Felice A. Nava, MD PhD Direttore U.O. Sanità Penitenziaria Azienda ULSS 6 Euganea Padova Direttore Comitato Scientifico Nazionale FeDerSerD HCV 0? Dall Eradicazione del virus alla

More information

Evaluation Report. Australian HIV Antiretroviral Guidelines Session. Australasian HIV/AIDS Conference Thursday 18 October 2012 Melbourne

Evaluation Report. Australian HIV Antiretroviral Guidelines Session. Australasian HIV/AIDS Conference Thursday 18 October 2012 Melbourne Evaluation Report Australian HIV Antiretroviral Guidelines Session Australasian HIV/AIDS Conference Thursday 18 October 2012 Melbourne 1 Table of Contents Background to the Antiretroviral Guidelines Conference

More information

Integrating Hepatitis C into Drug Treatment Settings

Integrating Hepatitis C into Drug Treatment Settings Integrating Hepatitis C into Drug Treatment Settings Substance Use Disorders Statewide Conference August 24, 2017 Pomona, CA Christine Rodriguez, MPH California Department of Public Health 1. Hepatitis

More information

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,

More information

Treatment of Hepatitis C in People Who Inject Drugs (PWIDs) Andrew Seaman, MD OHA P&T Meeting January, 2017

Treatment of Hepatitis C in People Who Inject Drugs (PWIDs) Andrew Seaman, MD OHA P&T Meeting January, 2017 Treatment of Hepatitis C in People Who Inject Drugs (PWIDs) Andrew Seaman, MD OHA P&T Meeting January, 2017 Conflicts of interest Receive

More information

Is Elimination of Hepatitis C Possible?

Is Elimination of Hepatitis C Possible? Is Elimination of Hepatitis C Possible? JORGE MERA, MD CHEROKEE NATION DISCLOSURE INFORMATION The presenter has nothing to disclose. Outline Scope of the problem Definitions Is elimination of HCV needed?

More information

Current trends in CHC 1st genotype treatment

Current trends in CHC 1st genotype treatment Current trends in CHC 1st genotype treatment Tarik Asselah MD, PhD Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France Disclosures Employee of Paris Public University

More information

Limiting the spread of hepatitis C virus with Treatment as Prevention (TasP)

Limiting the spread of hepatitis C virus with Treatment as Prevention (TasP) From TreatmentUpdate 197 Limiting the spread of hepatitis C virus with Treatment as Prevention (TasP) The idea of Treatment as Prevention, or TasP, has been proposed and is being implemented in some regions

More information

HEPATITIS C: CANADIAN CONTEXT

HEPATITIS C: CANADIAN CONTEXT 1 OPTIMAL ADHERENCE DURING HCV TREATMENT AMONGST ACTIVE DRUG USERS IN A COMMUNITY-BASED PROGRAM IN TORONTO, CANADA KATE MASON RESEARCHER SEPTEMBER 8, 2016 HEPATITIS C: CANADIAN CONTEXT 250,000 Canadians

More information

Sharing the Message of Hepatitis C and Liver Cancer in Indian Country

Sharing the Message of Hepatitis C and Liver Cancer in Indian Country Sharing the Message of Hepatitis C and Liver Cancer in Indian Country Jessica Leston, DrPH (c), MPH Northwest Portland Area Indian Health Board Clinical Programs Director - HIV/HCV Objectives Describe

More information

Physical activity. Policy endorsed by the 50th RACGP Council 9 February 2008

Physical activity. Policy endorsed by the 50th RACGP Council 9 February 2008 This paper provides a background to the Royal Australian College of General Practitioners (RACGP) current position on physical activity, as set out in the RACGP Guidelines for preventive activities in

More information

Models of HCV screening & treatment: An evidence-based international perspective

Models of HCV screening & treatment: An evidence-based international perspective Scottish University of the Year 2017 Models of HCV screening & treatment: An evidence-based international perspective Prof John F Dillon Page 1 Declaration of Financial Interests or Relationships Speaker

More information

Managing addictions via mobile applications: a smartphone app to assist management of cannabis use

Managing addictions via mobile applications: a smartphone app to assist management of cannabis use Managing addictions via mobile applications: a smartphone app to assist management of cannabis use Jan Copeland (PhD) Lisa Gibson Sally Rooke (PhD) UNSW Medicine Rationale 10.2% of Australians used cannabis

More information

Hepatitis C. Request a Test. Benefits of testing in AOD services to improve treatment uptake

Hepatitis C. Request a Test. Benefits of testing in AOD services to improve treatment uptake Hepatitis C Request a Test Benefits of testing in AOD services to improve treatment uptake Jenny Bourke Clinical Nurse Specialist Hepatitis C Community Clinic Christchurch About Hepatitis C Hepatitis is

More information

Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus

Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus JEFFREY NADELSON MD, ALAN EPSTEIN MD, THOMAS SEPE MD BOSTON UNIVERSITY SCHOOL OF MEDICINE ROGER WILLIAMS MEDICAL

More information

One State s Perspective on the Management of Hepatitis C Drugs. February 27, 2015 Pavel Lavitas, PharmD, BCPS Clinical Consultant Pharmacist

One State s Perspective on the Management of Hepatitis C Drugs. February 27, 2015 Pavel Lavitas, PharmD, BCPS Clinical Consultant Pharmacist One State s Perspective on the Management of Hepatitis C Drugs Pavel Lavitas, PharmD, BCPS Clinical Consultant Pharmacist Statement of Disclosure I have no relevant financial relationships that would be

More information

Utilization of Telemedicine to Treat Hepatitis C Virus Infection at a Medication Assisted Treatment Program

Utilization of Telemedicine to Treat Hepatitis C Virus Infection at a Medication Assisted Treatment Program Utilization of Telemedicine to Treat Hepatitis C Virus Infection at a Medication Assisted Treatment Program Collaborative Effort Between State University of New York - Buffalo Centers for Disease Control

More information

Shorter Durations and Pan-genotypic Regimens The Final Frontier. Professor Greg Dore

Shorter Durations and Pan-genotypic Regimens The Final Frontier. Professor Greg Dore Shorter Durations and Pan-genotypic Regimens The Final Frontier Professor Greg Dore Disclosures Funding and speaker fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences and Merck Efficacy Evolution

More information

Submission on the Draft National Clinical Practice Guidelines for Dementia in Australia

Submission on the Draft National Clinical Practice Guidelines for Dementia in Australia Submission on the Draft National Clinical Practice Guidelines for Dementia in Australia 4 June 2015 details Name of organisation Royal Australian College of General Practitioners () Postal Address Legal

More information

National Hepatitis plan. Dr JP Mulkay Clinic of Hepatology Department of Hepato Gastro entrology

National Hepatitis plan. Dr JP Mulkay Clinic of Hepatology Department of Hepato Gastro entrology National Hepatitis plan Dr JP Mulkay Clinic of Hepatology Department of Hepato Gastro entrology National hepatitis Plan Hepatitis B: plan non existent. People s migration from endemic countries. Reimbursement

More information

Telemedicine: Connecting Behavioral Health and Medical Care

Telemedicine: Connecting Behavioral Health and Medical Care Telemedicine: Connecting Behavioral Health and Medical Care Lawrence S. Brown, Jr., MD, MPH, FASAM CEO, START Treatment & Recovery Centers Clinical Associate Professor of Medicine and Health Care and Policy

More information

The Changing World of Hepatitis C

The Changing World of Hepatitis C The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures

More information

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.36 Subject: Daklinza Page: 1 of 8 Last Review Date: March 18, 2016 Daklinza Description Daklinza (daclatasvir)

More information

Hepatitis B and C in Australia. Annual Surveillance Report Supplement 2016

Hepatitis B and C in Australia. Annual Surveillance Report Supplement 2016 Hepatitis B and C in Australia Annual Surveillance Report Supplement 216 The Kirby Institute for infection and immunity in society 216 ISSN 226-163 (Online) This publication is available at Internet address

More information

Opt-out testing for blood-borne viruses in primary care:

Opt-out testing for blood-borne viruses in primary care: Research Mark O Kelly, David Byrne, Edward Naughten, Colm Bergin and Caroline Williams Opt-out testing for blood-borne viruses in primary care: a multicentre, prospective study Abstract Background Hepatitis

More information

Disclosures 29/09/2014. Genetic determinants of. HCV treatment outcome. IDEAL: IL28B-type is the strongest pre-treatment predictor of SVR

Disclosures 29/09/2014. Genetic determinants of. HCV treatment outcome. IDEAL: IL28B-type is the strongest pre-treatment predictor of SVR 29/9/214 Genetic determinants of ᴧ HCV treatment outcome Disclosures Advisory board member - Gilead, Abbvie, Bristol-Myers Squibb (BMS), Janssen, Merck, and oche Speaker - Gilead, Janssen, Merck, BMS,

More information

RACGP Immunisation Position Paper

RACGP Immunisation Position Paper THE ROYAL AUSTRALIAN COLLEGE OF GENERAL PRACTITIONERS RACGP Immunisation Position Paper Aim The prevention of disease through vaccination is readily available to all Australian children Principles Prevention

More information

Treatment of Hepatitis C. David Beking, BHSc, MPH Street Health Centre, Kingston ON Canadian Journal of Gastroenterology (accepted Sept.

Treatment of Hepatitis C. David Beking, BHSc, MPH Street Health Centre, Kingston ON Canadian Journal of Gastroenterology (accepted Sept. Treatment of Hepatitis C among IDUs: A multidisciplinary care approach David Beking, BHSc, MPH Street Health Centre, Kingston ON Canadian Journal of Gastroenterology (accepted Sept. 2012) Public health

More information

Current Treatments for HCV

Current Treatments for HCV Current Treatments for HCV Mitchell L. Shiffman, MD, FACG Advisory Committee/Board Member: Achillion, Anadys, Boehringer-Ingelheim, BMS, Conatus, Genentech, Gen-Probe, Gilead, Globeimmune, GSK, Janssen,

More information

HIV, HBV and HCV testing policy experiences and lessons learned.

HIV, HBV and HCV testing policy experiences and lessons learned. HIV, HBV and HCV testing policy experiences and lessons learned. Contents HIV and viral hepatitis: distinct epidemics at different stages of evolution Epidemiology: transmission, prevalence, incidence

More information

Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany

Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany PHC 2018 - www.aphc.info Disclosures Advisory boards:

More information

GENERAL PRACTICE LED EARLY DEMENTIA DETECTION IN A RURAL SETTING

GENERAL PRACTICE LED EARLY DEMENTIA DETECTION IN A RURAL SETTING GENERAL PRACTICE LED EARLY DEMENTIA DETECTION IN A RURAL SETTING A NEW MODEL OF CARE Presented by: Dr Adel Asaid (OAM) MBBCH FRACGP INNOVATIVE MODEL OF GP LED DEMENTIA DETECTION Aim: To develop a general

More information

The Role of Liver Societies in the Global Viral Hepatitis Response

The Role of Liver Societies in the Global Viral Hepatitis Response The Role of Liver Societies in the Global Viral Hepatitis Response Anna S. Lok, MD Alice Lohrman Andrews Research Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research

More information

HIV and HCV coinfection - Barriers in Central and Eastern Europe

HIV and HCV coinfection - Barriers in Central and Eastern Europe HIV and HCV coinfection - Barriers in Central and Eastern Europe Jerzy Jaroszewicz Vice President of Polish Association for the Study of Liver Department of Infectious Diseases and Hepatology, Medical

More information

Successful hepatitis C treatment lowers risk of death for people with HIV and HCV co infection

Successful hepatitis C treatment lowers risk of death for people with HIV and HCV co infection Successful hepatitis C treatment lowers risk of death for people with HIV and HCV co infection Liz Highleyman Produced in collaboration with hivandhepatitis.com Published: 28 October 2015 Jump to Trends

More information

Annual statement of progress Liver Disease Delivery Plan May 2017

Annual statement of progress Liver Disease Delivery Plan May 2017 Annual statement of progress Liver Disease Delivery Plan May 2017 Overview Liver disease is the third most common cause of premature death in the UK and the national liver disease health outcomes are worse

More information

Rosemary Plum Prescriptive Solutions Ltd SIMPLE Respiratory 2015

Rosemary Plum Prescriptive Solutions Ltd SIMPLE Respiratory 2015 + A SERVICE FOR COMMUNITY PHARMACY Rosemary Plum Prescriptive Solutions Ltd + n Why Pharmacy? High patient footfall 450 diagnosed asthma patients Walk-in service Medicines skills and expertise Structured

More information

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Daklinza Sovaldi Page: 1 of 7 Last Review Date: June 24, 2016 Daklinza Sovaldi Description Daklinza

More information

4 th largest seaside town in UK 2 nd most densely populated Most densely populated which is 100% seaside Typical presentation for a town of its

4 th largest seaside town in UK 2 nd most densely populated Most densely populated which is 100% seaside Typical presentation for a town of its Glyn Halksworth 4 th largest seaside town in UK 2 nd most densely populated Most densely populated which is 100% seaside Typical presentation for a town of its scale. Or is it? Tourism and alcohol Regional

More information